Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

Y0000700

Paclitaxel natural for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Paclitaxel

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C47H51NO14
CAS Number:
33069-62-4
Molecular Weight:
853.91
Beilstein:
1420457
MDL number:
MFCD00869953
UNSPSC Code:
41116107
PubChem Substance ID:
329831103
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

paclitaxel

manufacturer/tradename

EDQM

mp

213 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7

InChI

1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

InChI key

RCINICONZNJXQF-MZXODVADSA-N

Gene Information

human ... TUBA1A(7846) , TUBA1B(10376) , TUBA1C(84790) , TUBA3C(7278) , TUBA3E(112714) , TUBA4A(7277) , TUBB(203068) , TUBB1(81027) , TUBB2A(7280) , TUBB2B(347733) , TUBB3(10381) , TUBB4A(10382) , TUBB4B(10383) , TUBB6(84617) , TUBB8(347688)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Paclitaxel natural for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Paclitaxel is a potent anti-neoplastic and anti-mitotic taxane drug, which binds to the N-terminus of β-tubulin and and stabilizes microtubules arresting the cell cycle at the G2/M phase. The microtubule damage induces apoptosis through a JNK-dependent pathway followed by a JNK-independent pathway, perhaps related to the activation of protein kinase A (PKA) or of Raf-1 kinase, resulting in phosphorylation of Bcl-2. A major metabolite via CYP2CB is 6α-hydroxypaclitaxel (6α-OHP).

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Caution

Paclitaxel undergoes transesterification in methanol and hydrolyzes in aqueous solutions.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1720000

Xanthanoic acid, United States Pharmacopeia (USP) Reference Standard

Y0000698

Paclitaxel, European Pharmacopoeia (EP) Reference Standard

Y0000719

Paclitaxel semi-synthetic for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000739

Paclitaxel semi-synthetic for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0000699

Paclitaxel impurity C, European Pharmacopoeia (EP) Reference Standard

1491332

Paclitaxel, United States Pharmacopeia (USP) Reference Standard

1491354

Paclitaxel Related Compound B, United States Pharmacopeia (USP) Reference Standard

1491343

Paclitaxel Related Compound A, United States Pharmacopeia (USP) Reference Standard

1491365

Paclitaxel impurity mixture, United States Pharmacopeia (USP) Reference Standard

PHR1803

Paclitaxel, Pharmaceutical Secondary Standard; Certified Reference Material

01517

N-Cinnamoyl-N-debenzoylpaclitaxel, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

95185

N-Debenzoyl-N-(phenylacetyl)paclitaxel, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

29914

10-O-Deacetylpaclitaxel, reference material

PHR2112

Paclitaxel Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9146

7-O-Acetylpaclitaxel, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9149

7-epi-Paclitaxel, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9150

Paclitaxel impurity K, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR2111

Paclitaxel Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR3007

10-desacetyl-baccatin III, pharmaceutical secondary standard, certified reference material

PHR3261

Xanthanoic Acid, pharmaceutical secondary standard, certified reference material

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H341,H360FD,H372

Hazard Classifications

Muta. 2 - Repr. 1B - STOT RE 1

Target Organs

Central nervous system,Bone marrow,Cardio-vascular system

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

监管及禁止进口产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Denise A Yardley
Journal of controlled release : official journal of the Controlled Release Society, 170(3), 365-372 (2013-06-19)
Taxanes are a key chemotherapy component for several malignancies, including metastatic breast cancer (MBC), ovarian cancer, and advanced non-small cell lung cancer (NSCLC). Despite the clinical benefit achieved with solvent-based (sb) taxanes, these agents can be associated with significant and
M Onrubia et al.
Current medicinal chemistry, 20(7), 880-891 (2012-12-06)
Taxol (paclitaxel) and its derivatives are microtubule-stabilizing drugs widely used in the treatment of several types of cancer, including mammary, prostate, ovarian and non-small-cell lung carcinoma, as well as AIDS-associated Kaposi's sarcoma and other types of tumor. Taxanes stabilize microtubules
Stěpán Koudelka et al.
Journal of controlled release : official journal of the Controlled Release Society, 163(3), 322-334 (2012-09-20)
Over the past three decades, taxanes represent one of the most important new classes of drugs approved in oncology. Paclitaxel (PTX), the prototype of this class, is an anti-cancer drug approved for the treatment of breast and ovarian cancer. However
Taroh Satoh et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(19), 2039-2049 (2014-05-29)
In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) -positive tumors. The role of anti-HER2 agents, including lapatinib, in this setting and population is unclear.
Corey J Langer et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(19), 2059-2066 (2014-06-04)
Figitumumab (CP-751,871), a fully human immunoglobulin G2 monoclonal antibody, inhibits the insulin-like growth factor 1 receptor (IGF-1R). Our multicenter, randomized, phase III study compared figitumumab plus chemotherapy with chemotherapy alone as first-line treatment in patients with advanced non-small-cell lung cancer
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service